Skip to main content
CELZ logo

CELZ · Creative Medical Technology Holdings, Inc.

Track CELZ — free
$0.46 -0.01 (-2.42%)
Market Cap
$3.34M
Shares
7.60M
Volume · Nov 19 81.51K Avg daily vol (3M) 637.41K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.44 Open$0.46 Day$0.44–0.47 52W close$0.44–2.91 Avg vol 30d104K Short int66K · 0.9% of shares · 1.0d Short vol21% DataJan 2020–Nov 2026 Filing10-Q · Nov 6

Latest documents

2026
Nov 13
Current report 8-K Events of Nov 10
Nasdaq bid-price deficiency opens compliance grace period

Creative Medical Technology Holdings, Inc. received Nasdaq notice on November 10, 2026 after its bid price stayed below $1.00 per share for 30 business days. It has until May 10, 2027 to regain compliance for at least ten consecutive business days.

Delisting notice or listing transfer
2 source passages
On November 10, 2026, Creative Medical Technology Holdings, Inc. (the “Company”) received a letter from The Nasdaq Stock Market stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of the Company’s common stock was below $1.00 per share for 30 consecutive business days. Pursuant to Nasdaq’s Listing Rules, the Company has a 180 day grace period, until May 10, 2027, during which the Company may regain compliance if the bid price of its common stock closes at $1.00 per share or more for a minimum of ten consecutive business days. Open the document at this passage
Nov 10
Proxy statement DEF 14A
Five directors and evergreen share provision face stockholders

Creative Medical Technology Holdings, Inc. stockholders will vote on December 28, 2026 to elect five directors and approve an evergreen provision adding up to 5% of outstanding common shares annually from January 1, 2027 through January 1, 2031.

Read from the first part of this long document
4 source passages
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. We are pleased to invite you to attend our 2026 Annual Meeting of Stockholders to be held on December 28, 2026, at 9:00 a.m. Pacific Standard Time at 440 Stevens Avenue, Suite #200, Solana Beach, CA 92075 (the “Annual Meeting”). To elect five directors to our Board of Directors to serve until the next Annual Meeting of Stockholders or until their successors have been duly elected or appointed and qualified To approve an amendment to our 2021 Equity Incentive Plan (the “Equity Plan”) adopting an evergreen provision by which the number of reserved shares of Common Stock available for issuance under the Equity Plan will automatically increase on January 1, 2027 and on each subsequent January 1 through and including January 1, 2031, by up to 5% of the total number of shares of Common Stock issued and outstanding on December 31 of the immediately preceding calendar year Open the document at this passage
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net loss widens to $2,663,478

Creative Medical Technology Holdings reported no revenue and a $2,663,478 net loss for the three months ended September 30, 2026, versus $1,235,934 a year earlier. Available cash and US Treasuries totaled $6,845,741.

Revenue $0 Net loss $2.67M Diluted EPS -$0.40
Read from the MD&A section
4 source passages
Creative Medical Technology Holdings, Inc. No revenues were generated during the three-month periods ended September 30, 2026 and 2025. For the reasons stated above, our net loss for the three-months ended September 30, 2026, was $2,663,478 in comparison with a net loss of $1,235,934 for the comparable period a year ago. As of September 30, 2026, we had $6,845,741 of available cash and US Treasuries and positive working capital of approximately $6,643,493. Open the document at this passage
Sep 25
Current report 8-K Events of Sep 24
Entered into a material agreement, Unregistered sale of equity

On September 24, 2026, Creative Medical Technology Holdings, Inc. purchased 4,000,000 BioDefense, Inc. shares for $200,000 and 1,000,000 company shares, increasing its ownership to 16,000,000 shares, or 80%.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$3,000
Trailing 12 months
Net income (TTM)
−$7.47M
Trailing 12 months
Revenue growth YoY
-45.5%
Year over year
Operating margin
-256,435.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+158.1%
Year over year · more shares
Price change (1Y)
-84.7%
Trailing year
Short interest
0.9%
Latest settlement · 1.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −70%
below
Price vs 50-day avg −43%
below
RSI (14) 24
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −43%
trailing
6-month return −80%
trailing
YTD return −78%
this year
Relative strength −75%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+20% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.87% of shares out · ▼ -19.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
18 holders — near 3-yr high, broad support
Squeeze score 29
low risk · 0–100
Fundamentals
Strong
Revenue growth −45%
Y/Y
Gross margin 63%
expanding
EPS growth +32%
Y/Y
Quant / Vol
risk profile
Very High
Volatility 143%
annualized · 1-yr
Max drawdown −85%
past year
ATR 13.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−70% Bearish
Price vs 50-day avg
−43% Bearish
RSI (14)
24 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+20% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.87% of shares out · ▼ -19.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
18 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $3
vs 200-day avg -70% vs 50-day avg -43%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CELZ
Creative Medical Technology Holdings, Inc.
this stock
$3.34M -77.6% -45.5% — 0.9%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
18
% held
63.9%
Net QoQ
+4.5M sh
Top holder
MYDA Advisors LLC
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Falling
Shares short
66.2K
Days to cover
1.0d
Change
-15.9K sh
View
Short Volume
Short vol %
21%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
402
Value
$285
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
50.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$6.0K
Net income (FY)
$-6.0M
EPS diluted
$-2.52
View
Buybacks
Authorized
shares 43.1K
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 13, 2026
This year
15

Creative Medical Technology Holdings, Inc. received Nasdaq notice on November 10, 2026 after its bid price stayed below $1.00 per share for 30 business days. It has until May 10, 2027 to regain compliance for at least ten consecutive business days.

View
Exempt Offerings
Offering
$17.0M
Filed
May 5, 2022
View
Earnings & Events
Investor Relations
Latest news
Creative Medical Technology Holdi…
Published
Oct 20, 2026
View

Performance

5D 20D 120D MTD YTD
CELZ -28.6% -43.2% -80.4% -32.8% -77.6%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -23.2% -36.9% -74.8% -27.6% -82.5%

Capital returns

Buyback program · as of Feb 2, 2016
Authorized
shares 43,112
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1187953 CUSIP 22529Y408 13F (30d) 21 filings 20 filers Visit website Investor relations